Adjusted chemo dosing for hard-to-treat ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced ovarian, fallopian tube, or primary peritoneal cancer that is high-grade (aggressive).
- You are 18 years or older.
- You received 3 to 4 rounds of standard chemotherapy (carboplatin and paclitaxel) and it wasn't very effective.
- You had incomplete surgery to remove the tumor(s), or surgery was not possible.
- You are physically active (ECOG 0 or 1) meaning you can do most daily activities.
- Your blood counts and liver/kidney function are good enough for this chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
This Phase 3 trial studies a three-step “extra” chemotherapy plan after surgery for people with certain advanced ovarian, fallopian-tube, or primary peritoneal cancers. The goal is to improve outcomes by lowering the chance the cancer comes back.
This trial tests a new way to give heated chemotherapy directly into the abdomen during surgery for women aged 70 and older with advanced ovarian cancer. It aims to find a gentler treatment option that may still be effective for those who are more frail.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.